옵션 체인은 다양한 행사가격과 만기일에 대한 Entrada Therapeutics의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Entrada Therapeutics에 대한 시장 심리를 평가합니다..

Entrada Therapeutics (NASDAQ:TRDA) 주식, 옵션 체인

ENTRADA THERAPEUTICS INC

Entrada Therapeutics

Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics Inc

Lovesac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOVE#NASDAQ">LOVE</a>) affirms FY2026 GAAP EPS guidance from $0.80-$1.36 to $0.80-$1.36 vs $1.03 analyst estimate. Affirms FY2026 sales outlook from $700.00 million-$750.00 million to $700.00 million-$750.00 million vs $710.71 million estimate.

News

Guidance

LOVE

Lovesac Affirms FY2026 GAAP EPS Guidance of $0.80-$1.36 vs $1.03 Est; Affirms FY2026 Sales Guidance of $700.00M-$750.00M vs $710.71M Est

Lovesac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOVE#NASDAQ">LOVE</a>) is looking for Q2 GAAP EPS of $(0.83)-$(0.58) vs $(0.26) analyst estimate. sees sales of $157.000 million-$166.000 million vs $161.67 million analyst estimate.

Lovesac Sees Q2 GAAP EPS $(0.83)-$(0.58) vs $(0.26) Est; Sees Sales $157.000M-$166.000M vs $161.67M Est

Innovative Agents Highlight Growth of Targeted Protein Degradation Platform and BMS' Leadership in Innovative Cancer Therapies
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bms.com%2F&amp;esheet=54272918&amp;newsitemid=20250612347504&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=d564e2f69d9f1c2ea34e8ca51e3ad252">Bristol Myers Squibb</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) today announced the presentation of new data from its targeted protein degradation platform during the 2025 European Hematology Association (EHA) Annual Congress being held from June 12-15 in Milan, Italy. Presentations feature updated clinical findings on the company's investigational oral CELMoD&#x2122; agents mezigdomide and iberdomide in multiple myeloma, and golcadomide in non-Hodgkin lymphoma, as well as the first results evaluating the company's first-in-class, oral BCL6 ligand-directed degrader (LDD) (BMS-986458) in non-Hodgkin lymphoma.
The latest data presented for the three lead CELMoD agents and BCL6 LDD underscore the potential impact that these therapies may have in addressing significant unmet medical needs in hematologic malignancies. These agents are part of continuing research across targeted protein degradation at Bristol Myers Squibb, which also encompasses additional CELMoD agents, LDDs and degrader antibody conjugates (DACs) across blood cancers and solid tumors, as well as non-malignant hematologic disorders.
Protein degraders, like CELMoD agents and LDDs, are therapies designed to target and degrade specific proteins that drive diseases, including many proteins that are difficult to target through conventional small-molecule inhibitors. These innovative agents have the possibility to enhance the efficacy of existing therapies and overcome resistance in various malignancies, potentially improving patient outcomes.

Bristol Myers Squibb Presents Updated Clinical Findings On CELMoD Agents Mezigdomide And Iberdomide In Multiple Myeloma, Golcadomide In Non-Hodgkin Lymphoma, And First Results Evaluating Oral BCL6 LDD In Non-Hodgkin Lymphoma, At EHA 2025

Lovesac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOVE#NASDAQ">LOVE</a>) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.83) by 12.05 percent. This is a 12.05 percent increase over losses of $(0.83) per share from the same period last year. The company reported quarterly sales of $138.37 million which beat the analyst consensus estimate of $137.00 million by 1.00 percent. This is a 4.32 percent increase over sales of $132.64 million the same period last year.

Earnings

Earnings Beats

Lovesac Q1 EPS $(0.73) Beats $(0.83) Estimate, Sales $138.37M Beat $137.00M Estimate

<ul>
<li>Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech's next key milestone in the execution of its oncology strategy</li>
<li>Acquisition of CureVac will complement BioNTech's capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing</li>
<li>Public exchange offer for all shares of CureVac where each share of CureVac will be exchanged for approx. $5.46 in BioNTech American Depositary Shares ("ADSs"), representing a premium of 55% to CureVac's three-month volume weighted average price of approx. $3.53 as of June 11, 2025</li>
<li>All-stock acquisition has potential to create long-term value for both companies' shareholders given their complementary capabilities, focus on mRNA innovation, and shared vision</li>
<li>Transaction is supported by CureVac's major shareholder dievini Hopp BioTech holding GmbH &amp; Co. KG and certain of its affiliates and expected to close in 2025&nbsp;</li>
</ul>

Biotech

Large Cap

Health Care

General

BNTX

CVAC

BioNTech Agrees To Acquire CureVac In All-stock Transaction

HC Wainwright &amp; Co. analyst Brandon Folkes assumes Connect Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTB#NASDAQ">CNTB</a>) with a Buy rating and announces Price Target of $7.

Price Target

Initiation

Analyst Ratings

CNTB

HC Wainwright & Co. Assumes Connect Biopharma Hldgs at Buy, Announces Price Target of $7

Tech billionaire and Shark Tank investor Robert Herjavec once credited a part-time retail job for equipping him with the tools that led to his eventual success in the world of business.
What Happened: Speaking to Lewis Howes on a podcast in February, Herjavec shared his inspiring story. When he was young, Herjavec went to Harry Rosen, a luxury clothing retailer in Canada, but the $1200 suit was too expensive for him. The shop attendant informed him that employees received 50% discounts on suits, so Herjavec took up a part-time job at the store.
Herjavec, who billionaire and fellow Shark Tank investor Mark Cuban described as being interested in <a href="https://www.benzinga.com/news/25/01/42898869/she-cant-do-math-and-hes-the-bad-guy-billionaire-mark-cuban-ranks-all-the-sharks-on-shark-tank">&#8220;pets and kids and stuff like that&#8221;</a> in his investments, shared: "The guy who owns the place called Harry Rosen … used to teach on Saturdays if you showed up an hour before the store opened." Herjavec showed up, unlike his colleagues, and found himself on the receiving end of a mentorship that covered everything from tailoring basics to client psychology.
See Also: <a href="https://www.benzinga.com/markets/tech/25/06/45851993/mr-wonderful-kevin-oleary-says-he-was-once-told-by-a-ceo-to-shut-up-and-that-leveled-up-his-negotiation-skills-fellow-shark-mark-cuban-also-fle">Mr Wonderful, Kevin O&#8217;Leary, Says He Was Once Told By A CEO To &#8216;Shut Up&#8217; And That Leveled Up His Negotiation Skills — Fellow &#8216;Shark&#8217; Mark Cuban Also Flexes This Superpower</a>
Why It Matters: Highlighting the importance of what he learnt from Rosen, Herjavec said, "I would have paid him to teach me." "It was great, he taught me everything," he added. He later made headlines for his $30.2 million sale of BRAK Systems to AT&amp;T Canada and a private equity deal for his Herjavec Group in 2021.
"I&#8217;m not wealthy because of my knowledge of a task, I&#8217;m wealthy because of my knowledge of sales," he explained.
Despite his success, Herjavec continues to share new lessons that he learnt from others, including from an <a href="https://www.benzinga.com/startups/24/10/41600192/robert-herjavec-jokes-about-working-to-get-a-bigger-jet-than-mark-cubans-cubans-which-one-response-h">interaction with Cuban</a>, which taught him to refocus on his own goals instead of comparing his achievements with others'.
Last year, he also shared an anecdote about asking Cuban why he dresses like a "slob," to which Cuban replied, <a href="https://www.benzinga.com/personal-finance/25/05/45211673/billionaire-mark-cuban-was-asked-by-fellow-shark-tank-star-with-all-due-respect-why-do-you-dress-like-a-slob-he-responded-because-i-can">"because I can,"</a> highlighting the freedom and power that comes with accumulating a massive amount of wealth.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Shark Tank Host: My Parents &amp; I Escaped Communism With $20! THIS Unlocked Wealth for Me!" width="500" height="281" src="https://www.youtube.com/embed/M2e0WeBCYIs?start=2&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/topics/25/06/45889687/mark-cuban-predicts-ai-video-will-trigger-an-explosion-in-face-to-face-engagement-events-and-jobs-calls-it-the-milli-vanilli-effect">Mark Cuban Predicts AI Video Will Trigger &#8216;An Explosion&#8217; In Face-To-Face Engagement, Events And Jobs. Calls It &#8216;The Milli Vanilli Effect&#8217;</a></li>
</ul>
Photo courtesy: DFree / Shutterstock.com

Entrepreneurship

Shark Tank Star Robert Herjavec Says A Part-Time Job Made Him A Billionaire, Thanks To A Retail Mentor Who Taught Him How To Sell To The Wealthy

Macro Economic Events

Econ #s

Economics

INDA

India Consumer Price Index (YoY) For May 2.82% Vs. 3.00% Est.; 3.16% Prior

HC Wainwright &amp; Co. analyst Heiko Ihle maintains Westwater Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/WWR#AMEX">WWR</a>) with a Buy and lowers the price target from $2.5 to $2.

HC Wainwright & Co. Maintains Buy on Westwater Resources, Lowers Price Target to $2

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/12082317/Biogene-01-900x600-1.png" alt="" class="wp-image-14317" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/12082317/Biogene-01-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/12082317/Biogene-01-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/12082317/Biogene-01-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
A squabble involving false advertising claims by a sinking Bloomage Biotech against highflying rival Giant Biogene has captivated China, with no end in sight
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>Shares of Giant Biogene have plunged 30% in the month since it was accused of false advertising by rival Bloomage Biotech</li>
<li>Biogene's stock had more than doubled before the squabble on success of its collagen skincare products, making it vulnerable to an attack by its jealous rival</li>
</ul>
A fight between skincare brands owned by two of China's wealthiest women has mesmerized the country with saturation media coverage – and left one of the pair's formerly highflying stocks badly bruised.
In nearly a month since the skirmish began on May 17, shares of&nbsp;Giant Biogene Holding Co. Ltd.&nbsp;(2367.HK) have shed nearly 30% of their value, while&nbsp;Bloomage BioTechnology Corp. Ltd.&nbsp;(688363.SH), which initiated the dust-up, is up about 7%.&nbsp;
While the allegations have the potential to dent both companies' reputations, the selloff for Biogene's stock, in particular, seems overblown. In its latest annual results, Biogene reported its revenue soared 57.2% last year to 5.5 billion yuan ($765 million), fueling a 42.4% profit gain to 2 billion yuan. Bloomage is moving in the other direction, reporting its revenue fell 12% last year to 5.37 billion yuan, as its profit plunged 71% to 174 million yuan.
So, how did this squabble between rising beauty Biogene and a fading Bloomage begin?&nbsp;
The two are known for different core products. Bloomage's use hyaluronic acid (HA), which helps the skin retain moisture. Biogene uses recombinant collagen, which helps new cells grow in the skin layer. Recombinant collagen has become all the rage lately, fueling Biogene's rapid rise and prompting Bloomage to invest in that area as well.
The fight may also have a personal element, either real or perceived, with much of the media attention focused on presumed tension between Biogene founder Fan Daidi and Bloomage founder Zhao Yan, two of China's wealthiest women.
Fan, a biochemist and former visiting scholar at MIT, founded Biogene in 2000 and built it into an industry-leading brand in 2024, according to Euromonitor. Its star product, "Comfy Collagen Stick" ranked first in sales on e-commerce platforms in China during the June 18 shopping festival last year.
Zhao started out as a banker, launching Bloomage in 2001 with an initial focus on the raw materials market for HA. In 2017 her company acquired Revitacare, a French maker of HA compounds. Bloomage then launched Biohyalux, a heavily discounted skincare brand, and has 44% of the global market for HA raw materials.
Bloomage fired the first shot in the battle by publishing a 5,000-word report on its official WeChat account accusing nine equity research houses of playing up the merits of recombinant collagen over HA. "The HA industry has encountered lies and trampling, and has been described as ‘outdated,' ‘not as safe as a certain substance,' ‘not as biologically active as a certain substance,' ‘not as market-valuable as a certain substance,'" the report said, in a thinly veiled reference to recombinant collagen.
A media field-day ensued, with some reports likening Zhao to a Chinese empress taking aim at imperial powers from the West.
The battle heated up 10 days later when beauty influencer Hao Yu, better known as "Dr. Big Mouth," who made headlines after previously accusing an Estee Lauder product of false advertising and discrimination against Chinese, took aim at Biogene. In his attack, Hao claimed the company had violated China's cosmetic labeling regulations after he found only trace levels of recombinant collagen in a Comfy product he tested.
<h4 class="wp-block-heading">Quick rebuttal</h4>
The Comfy brand quickly released a statement saying that it had immediately conducted tests showing more than 0.1% collagen content, well above Hao's finding of just 0.0177%. Biogene also commissioned third party testing agents to conduct independent tests.
Bloomage admitted days later that Hao was effectively on its payroll through an investment relationship.
But that didn't end the fight. On June 4, Comfy shared the test results on its website, saying it had not made any "false or misleading" claims for its product. One of the testing agencies cited by Hao also accused him of using its test results without permission and issued a letter of apology cited by Biogene.
That didn't stop Hao from continuing the fight, accusing Biogene a day later of pressuring testing institutions not to test the company's recombinant collagen products. He added that he had received a message from one such major company refusing to conduct a test because it didn't want to get caught up in the slugfest.
There are plenty of signs that financial pressure on Bloomage may have been partly behind its attacks against its up-and-coming rival. Bloomage previously delayed publication of its full-year results for 2024, publishing them just two weeks before its first-quarter results. Its first-quarter financials were also weak, showing the company's revenue fell 20.7% year-on-year to 1 billion yuan.
In addition to weak financials, Bloomage is also being plagued by other issues, including executive departures, changes to its management team and an internal anti-corruption campaign.
Revenue from Bloomage's skincare products declined by 32% in 2024 to 2.57 billion yuan, accounting for 48% of total revenue. According to Wind data, the company's market value peaked at 140 billion yuan in 2021, and has shriveled since then to a current 26 billion yuan. In December 2024, it was removed from the CSI 300 Index for China's most important publicly traded companies.
Meanwhile, Giant Biogene has moved in the opposite direction. Its revenue and net income both doubled between 2022 and 2024, and the company raised $80 million in its 2022 Hong Kong IPO. Since then, its stock has more than doubled from its IPO price of HK$24.30 to its latest close of HK$60.60 on Wednesday, giving the company a market cap of about HK$61 billion ($7.8 billion). The company is in a market that will growth by an average 55% annually between 2022 and 2027 to reach 64.5 billion yuan, according to independent research.
Biogene is hardly the only Chinese company benefitting from recent positive publicity for recombinant collagen skincare products. Other beneficiaries include&nbsp;Jinbo Bio-Pharmaceutical,&nbsp;Guangdong Marubi Biotechnology&nbsp;(603983.SS), and&nbsp;FREDA&nbsp;(600223.SS). But as the Biogene-Bloomage dust-up shows, highflying companies – and their investors – often make easy targets for jealous rivals.

Asia

Global

Opinion

Giant Biogene Bruised In A 'Battle Of The Skincare Belles'

Keybanc analyst David Tarantino initiates coverage on Modine Manufacturing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOD#NYSE">MOD</a>) with a Overweight rating and announces Price Target of $125.

Keybanc Initiates Coverage On Modine Manufacturing with Overweight Rating, Announces Price Target of $125

HC Wainwright &amp; Co. analyst Kevin Dede reiterates Digi Power X (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGXX#NASDAQ">DGXX</a>) with a Buy and maintains $2.5 price target.

Reiteration

DGXX

HC Wainwright & Co. Reiterates Buy on Digi Power X, Maintains $2.5 Price Target

Wallbox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBX#NYSE">WBX</a>), a global leader in electric vehicle (EV) charging and energy management solutions, today announced the expansion of its partnership with ENSOL EV, the e-mobility division of Texas-based Ensol Energy Solutions LLC. This next phase of the collaboration includes the deployment of Wallbox's Supernova DC fast chargers across key urban centers and transit corridors locations in Texas, Florida, and Georgia, three states experiencing rapid growth in EV adoption and charging demand.
Initial installations are scheduled to begin in the second half of 2025, with additional sites to follow through early 2026. The Supernova fast charger delivers up to 180 kW of power and includes integrated smart charging features for optimal energy distribution and uptime performance.
 &nbsp;

Wallbox Expands Partnership With ENSOL EV To Deliver Fast Charging Infrastructure In Texas, Florida, And Georgia

ADC Therapeutics SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it has entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in a $100.0 million private investment in public equity ("PIPE") financing. In the PIPE, ADC Therapeutics is selling 13.0 million common shares at $3.53 per share and pre-funded warrants to purchase 15.7 million common shares at $3.43, per pre-funded warrant, which is the price per common share in the PIPE minus the exercise price of CHF 0.08 per pre-funded warrant.
&nbsp;
Gross proceeds from the PIPE financing are anticipated to be approximately $100.0 million before deducting placement agent fees and offering expenses. The PIPE is expected to close on June 16, 2025, subject to customary closing conditions. ADC Therapeutics intends to use the net proceeds from the PIPE to fund multiple catalysts primarily in support of ZYNLONTA&#xAE;&nbsp;clinical development as well as ZYNLONTA commercialization activities, working capital and general corporate purposes.

Offerings

ADCT

ADC Therapeutics Raises $100M in Private Stock Deal of 13M Shares at $3.5/Share And Warrants To Purchase 15.7M Shares At $3.43/Pre-funded Warrant to Boost Cancer Drug Development

WestPark Capital analyst Curtis Shauger maintains Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) with a Buy and raises the price target from $195 to $246.

ORCL

WestPark Capital Maintains Buy on Oracle, Raises Price Target to $246

On Wednesday, June 11, U.S. markets ended lower. The S&amp;P 500 slipped as investors grew wary over Middle East tensions and a reported embassy evacuation. A mild inflation report eased fears about tariff-driven price hikes, boosting hopes for future rate cuts.
Despite a tentative U.S.-China trade deal, skepticism lingered. Most sectors ended lower, with Amazon and Nvidia weighing heavily on the market.
According to economic data, the Bureau of Labor Statistics reported annual inflation at 2.4% in May, with core inflation steady at 2.8%, both slightly below expectations.
Most S&amp;P 500 sectors ended lower Wednesday, led by losses in materials, communication services, and consumer discretionary, while energy and utilities closed higher.
The Dow closed almost flat at 42,865.77, the S&amp;P 500 declined 0.27% to 6,022.24, and the Nasdaq slid 0.50% to 19,615.88.
<h2 class="wp-block-heading">Asia Markets Today</h2>
On Thursday, Japan&#8217;s Nikkei 225 closed 0.68% lower at 38,161.00, led by losses in the Paper &amp; Pulp, Transport and Communication sectors.
Australia&#8217;s S&amp;P/ASX 200 was down 0.31% at 8,565.10, led by losses in the Materials, Metals &amp; Mining and Resources sectors.
India&#8217;s Nifty 50 was down 1.06% at 24,871.70, and the Nifty 500 slid 1.29% to 23,036.05.
China&#8217;s Shanghai Composite was up 0.01% at 3,402.66, and Shanghai Shenzhen CSI 300 fell 0.06% to 3,892.20.
Hong Kong&#8217;s Hang Seng closed the session 1.36% lower at 24,035.38.
<h2 class="wp-block-heading">Eurozone at 05:45 AM ET</h2>
The European STOXX 50 index was down 0.91%.
Germany&#8217;s DAX index declined 1.23%.
France&#8217;s CAC 40 fell 0.61%.
U.K.&#8217;s FTSE 100 index traded lower by 0.16%.
<h2 class="wp-block-heading">Commodities at 05:45 AM ET</h2>
Crude Oil WTI was trading lower by 1.35% at $67.24/bbl, and Brent was down 1.35% at $67.47/bbl.
Oil prices fell as traders weighed rising Middle East tensions and a planned U.S.-Iran meeting following a sharp rally on supply disruption fears.
Natural gas rose 2.54% to $3.595.
Gold traded higher by 1.27% to $3,385.72, Silver slid 0.57% to $36.005, and Copper fell 0.37% to $4.7965.
Gold surged as safe-haven demand rose on Middle East tensions and tariff fears, while a weak dollar and uncertainty over U.S.-China trade talks boosted broader metal prices.
<h2 class="wp-block-heading">U.S. Futures</h2>
As of 5:45 AM ET, the Dow Jones futures were down 0.57%, the S&amp;P 500 declined 0.38%, and the Nasdaq 100 was down 0.31%.
<h2 class="wp-block-heading">Forex</h2>
As of 5:45 AM ET, the U.S. Dollar Index declined 0.71% to 97.96, USD/JPY was down 0.64% to 143.61, and USD/AUD slid 0.01% to 1.5381.
The dollar neared a 2025 low, and global stocks slipped as rising Middle East tensions and trade uncertainty pushed investors toward safe havens like gold, the yen, and the franc.
Photo via Shutterstock

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia And Europe Markets Slide, Dollar Softens On Inflation Data And Geopolitical Worries - Global Markets Today While US Slept

Needham analyst Ami Fadia reiterates Praxis Precision Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>) with a Buy and maintains $80 price target.

PRAX

Needham Reiterates Buy on Praxis Precision Medicine, Maintains $80 Price Target

Acquisition would offer TELUS Digital shareholders liquidity at a compelling value and enhance TELUS Digital's ability to effectively respond to changing market dynamicsCloser operational integration between TELUS and
<ul>
<li>Acquisition would offer TELUS Digital shareholders liquidity at a compelling value and enhance TELUS Digital's ability to effectively respond to changing market dynamics</li>
<li>Closer operational integration between TELUS and TELUS Digital to supercharge AI and SaaS transformation across telecommunications, health, agriculture and consumer goods sectors</li>
<li>TELUS Digital to continue as a key enabler to TELUS' growth strategy and operational efficiency</li>
</ul>

TIXT

TELUS Proposes Full Acquisition of TELUS Digital To Accelerate AI And SaaS Transformation Across Core Business Sectors

<ul>
<li>MOBILIZE-1 is the first Phase 3 study being initiated for V181 as part of a planned robust clinical development program</li>
<li>Study will evaluate a single dose of V181 for the prevention of dengue disease caused by any of the four serotypes of the dengue virus regardless of previous exposure</li>
</ul>

Merck Has Initiated MOBILIZE-1 Phase 3 Trial For Single Dose Of V181, An Investigational Quadrivalent Vaccine, For The Prevention Of Dengue Disease Caused By Any Of The Four Dengue Virus Serotypes. Recruitment For The Trial Has Begun, And The First Participants Are Now Enrolling In Singapore

Needham analyst Bernie McTernan reiterates Chewy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) from Hold to Hold.

CHWY

Needham Reiterates Hold on Chewyto Hold

Press Releases

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Azenta Announces the Election of Dipal Doshi to its Board of Directors

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Entrada Therapeutics Reports First Quarter 2025 Financial Results

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Comments

Entrada Therapeutics

Entrada Therapeutics (TRDA) 옵션

Entrada Therapeutics (NASDAQ:TRDA) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌